Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Plain-language guide to PMID 20236700 (2010): double-blind randomized controlled trial of Neprilysin in 1328 patients, low blood pressure and orthostatic hypotension.

Key Facts

PMID: 20236700
Journal: Lancet (London, England)
Year: 2010
Study type: Randomized Controlled Trial
Authors: Ruilope LM et al. (6 authors)
DOI: 10.1016/S0140-6736(09)61966-8
Registered trial: NCT00549770

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Neprilysin in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

LCZ696 is a first-in-class inhibitor of the angiotensin II receptor and neprilysin.

The researchers aimed to establish whether the dual actions of LCZ696 lead to further lowering of blood pressure, compared with the angiotensin-receptor blocker valsartan.

Who Took Part

According to the abstract, 1328 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Neprilysin group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Neprilysin.

A placebo (an inactive look-alike) gave the Neprilysin group a baseline to be compared against.

Analysis was by intention to treat.

This trial is registered with ClinicalTrials.gov, number NCT00549770.

What Was Measured

Topics PubMed links to this paper include Aminobutyrates, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Biphenyl Compounds, Blood Pressure, Drug Combinations and Hypertension.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Neprilysin in 1328 patients in people with low blood pressure and orthostatic hypotension.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Lancet (London, England)), a journal based in England.

More context: Low blood pressure and orthostatic hypotension research.

Low blood pressure and orthostatic hypotension research

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.